Your browser doesn't support javascript.
loading
Historical Evolution and Provider Awareness of Inactive Ingredients in Oral Medications.
Reker, Daniel; Blum, Steven M; Wade, Peter; Steiger, Christoph; Traverso, Giovanni.
Affiliation
  • Reker D; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.
  • Blum SM; Department of Biomedical Engineering , Duke University , Durham, North Carolina, 27708, USA.
  • Wade P; Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA.
  • Steiger C; MIT-IBM Watson AI Lab, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.
  • Traverso G; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.
Pharm Res ; 37(12): 234, 2020 Oct 29.
Article in En | MEDLINE | ID: mdl-33123783
ABSTRACT

PURPOSE:

A multitude of different versions of the same medication with different inactive ingredients are currently available. It has not been quantified how this has evolved historically. Furthermore, it is unknown whether healthcare professionals consider the inactive ingredient portion when prescribing medications to patients.

METHODS:

We used data mining to track the number of available formulations for the same medication over time and correlate the number of available versions in 2019 to the number of manufacturers, the years since first approval, and the number of prescriptions. A focused survey among healthcare professionals was conducted to query their consideration of the inactive ingredient portion of a medication when writing prescriptions.

RESULTS:

The number of available versions of a single medication have dramatically increased in the last 40 years. The number of available, different versions of medications are largely determined by the number of manufacturers producing this medication. Healthcare providers commonly do not consider the inactive ingredient portion when prescribing a medication.

CONCLUSIONS:

A multitude of available versions of the same medications provides a potentially under-recognized opportunity to prescribe the most suitable formulation to a patient as a step towards personalized medicine and mitigate potential adverse events from inactive ingredients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmaceutic Aids / Clinical Competence / Drug Compounding / Prescription Drugs Limits: Humans Language: En Journal: Pharm Res Year: 2020 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmaceutic Aids / Clinical Competence / Drug Compounding / Prescription Drugs Limits: Humans Language: En Journal: Pharm Res Year: 2020 Document type: Article Affiliation country: United States
...